PropertyValue
?:abstract
  • Severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) is the virus that causes coronavirus disease 2019 (COVID-19); a worldwide pandemic as declared by the World Health Organization (WHO). SARS-CoV-2 appears to infect cells by first binding and priming its viral-spike proteins with membrane-associated angiotensin-converting enzyme 2 (ACE2) and transmembrane protease serine 2 (TMPRSS2). Through the coordinated actions of ACE2 and TMPRSS2, SARS-CoV-2 spike proteins fuse with plasma membranes and ultimately the virus enters cells. ACE2 is integral to the renin-angiotensin-aldosterone system (RAAS), and SARS-CoV-2 down-regulates protein expression levels of ACE2. Once infected, patients typically develop acute respiratory distress syndrome (ARDS) and a number of other severe complications that result in a high rate of fatality, especially in older (>60 years) adults and in people with pre-existing medical conditions. Data now indicate clearly that among people of all age groups, COVID-19 fatalities are higher in men than women. Here, attention is focused on these sex differences and posit a role of estrogen in these differences as well as possible therapeutic and protective actions of 17β-estradiol against COVID-19.
is ?:annotates of
?:creator
?:doi
  • 10.46439/allergy.1.010
?:doi
?:journal
  • J_Allergy_Infect_Dis
?:license
  • cc-by
?:pdf_json_files
  • document_parses/pdf_json/9ccbab14146252ab305278416bb2832a6e708290.json
?:pmc_json_files
  • document_parses/pmc_json/PMC7665224.xml.json
?:pmcid
?:pmid
?:pmid
  • 33196058.0
?:publication_isRelatedTo_Disease
is ?:relation_isRelatedTo_publication of
?:sha_id
?:source
  • Medline; PMC
?:title
  • Possible protective role of 17β-estradiol against COVID-19
?:type
?:year
  • 2020-08-19

Metadata

Anon_0  
expand all